Corvus Pharmaceuticals公布队列4积极数据 确认Soquelitinib治疗特应性皮炎安慰剂对照1期临床试验结果

美股速递
Jan 20

Corvus Pharmaceuticals宣布,其队列4的积极数据进一步确认了Soquelitinib在治疗特应性皮炎的安慰剂对照1期临床试验中所取得的成果。这一进展为该公司在免疫疾病治疗领域的研发增添了重要砝码。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10